டெஸ்டோஸ்டிரோன் அடக்குமுறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டெஸ்டோஸ்டிரோன் அடக்குமுறை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டெஸ்டோஸ்டிரோன் அடக்குமுறை Today - Breaking & Trending Today

High-Tech Lynching at DePaul | Frontpagemag


Fri Feb 5, 2021
The Left’s thought police at DePaul University in Chicago have come after Dr. Jason D. Hill, a tenured professor of philosophy and a Shillman Journalism Fellow at the David Horowitz Freedom Center. The leftwing fascists treat every expression of views they don’t like on a controversial issue as evidence of bigotry against one or another so-called “oppressed” minority. The censors demand conformity or punishment for dissenting views.
In Dr. Hill’s case, one of his former students, Grace Gallant, charged that he is violently transphobic.” Gallant claimed the professor “said that we would be discussing ‘if a biological man could ever be a woman.’” Gallant complained that this alleged remark Dr. Hill is accused of making was “not just offensive and hurtful, but it’s so archaic, useless and immature to have these kinds of conversations in class.” ....

United States , Depaul University , Timothy Roberts , Jasond Hill , Selina Soule , Faculty Council , University Of Missouri , Kansas City School Of Medicine , David Horowitz Freedom Center , Us Air , Shillman Journalism Fellow , David Horowitz Freedom , Grace Gallant , Professor Hill , Gender Equity , New England , Joshua Safer , Transgender Medicine , Mount Sinai Hospital , Female Category , Testosterone Suppression , Performance Advantage , Associate Professor , Missouri Kansas City School , ஒன்றுபட்டது மாநிலங்களில் , தெப்போுல் பல்கலைக்கழகம் ,

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)


SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)
(UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
This debate follows the publication of the HERO trial,

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal of Medicine in June 2020 and of which Dr. Shore is the lead author. This was a randomized controlled comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide. 120mg relugolix was given by mouth daily and leuprolide was given every 3 months as depot injections. The primary end point was “sustained castration”, meaning a testosterone level ....

United States , Fox Chase Cancer Center , Marshall Strother , Ashley Ross , Ashley Evan Ross , Society Of Urologic Oncology Annual Meeting , Carolina Urologic Research Center , Division Of Urologic Oncology , Meeting Of The Society Urologic Oncology , United States Federal Drug Administration , Northwestern Medical Group , Health Drug , Feinberg School Of Medicine , Society For Urologic Oncology , Urologic Oncology , Neal Shore , Men With Advanced Prostate Cancer , New England Journal , Medical Director , Carolina Urologic Research , Associate Professor , Feinberg School , Northwestern Medical , Urologic Oncology Fellow , Urologic Oncology Annual Meeting , Treatment Patterns ,